$1.54
-0.09 (-5.52%)
Open$1.57
Previous Close$1.63
Day High$1.59
Day Low$1.50
52W High$116.00
52W Low$1.48
Volume—
Avg Volume808.1K
Market Cap1.96M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,039.0% upside
Current
$1.54
$1.54
Target
$48.34
$48.34
$29.39
$48.34 avg
$58.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.75M | 1.85M | 1.56M |
| Net Income | -488,923 | -548,272 | -518,591 |
| Profit Margin | -27.9% | -29.7% | -33.3% |
| EBITDA | -843,788 | -899,520 | -655,593 |
| Free Cash Flow | -343,922 | -223,177 | -234,743 |
| Rev Growth | +4.0% | +6.5% | +13.9% |
| Debt/Equity | 0.91 | 0.97 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |